Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longidaza for Residual Lung Changes After COVID-19
NCT06383819Phase 3Completed
- Sponsor
- Petrovax Pharm
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Polymer-based Nanoparticles, Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post acute COVID-19 syndrome and pulmonary fibrosis (PF) comparing Longidaza with Placebo (2 arms). Primary endpoint: Change in Forced Vital Capacity (FVC) from Baseline to Day 71. Started Apr 2022; status: completed.
02
Drugs
bovhyaluronidase azoximer
03
Conditions
post acute COVID-19 syndromepulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT06383819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383819.